Asset Management for Growing Biotech Companies - Biotech companies with new facilities are uniquely positioned to implement and benefit from a regulatory asset management (RAM) system. - BioPharm

ADVERTISEMENT

Asset Management for Growing Biotech Companies
Biotech companies with new facilities are uniquely positioned to implement and benefit from a regulatory asset management (RAM) system.


BioPharm International


Most calibration departments rely on a computerized calibration management system (CCMS) to manage and document calibration activity. These systems are designed to meet the needs of a calibration department, including an instrument-centric approach and features such as measurement data templates and reverse standards traceability.

Just as regulations require that regular calibrations be performed on equipment, regular preventive maintenance also must be performed. This maintenance not only satisfies regulatory requirements for maintaining equipment in its original working order, but also reduces the likelihood that more costly and disruptive emergency maintenance will be required. The challenge is to determine the optimal frequency for preventive maintenance, just as the calibration professional must strive to establish the optimal frequency and tolerances for calibration readings.

Any changes to the asset (i.e., when a similar replacement part is no longer available and new alternatives must be considered), will require change control and completion of review and approval procedures before the asset can return to use. Speedy resolution of change control and like-for-like replacement issues can make a huge difference on the bottom line when dealing with a multimillion dollar piece of equipment or process line. In addition, when operating a maintenance group, managing a pool of people and ensuring that the right person is available for each job is a constant challenge.

To manage all the complications of asset maintenance, many companies use computerized maintenance management systems (CMMS). Activity in CMMS tends to be organized around work orders. If a CMMS was designed for use by biopharmaceutical manufacturers, it can offer a way to manage replacement parts approved for each asset in the validated state.

A Systems-Based Approach

The Food and Drug Administration and other similar regulatory agencies have started to take a top-down, system-based approach to inspections and audits, called the quality systems inspection technique (QSIT). Instead of looking solely at the end results of processes or focusing on detecting small variations, QSIT focuses on the major elements of the total quality system that are most critical to meeting requirements. As part of implementing this new technique, regulatory agencies are training their inspectors in new areas of focus, including, for example, various disciplines in asset management.


Quality Systems: Facilities and Equipment
The FDA has grouped Facility and Equipment controls into one of five manufacturing subsystems that make up a complete quality system. According to FDA, the Facilities and Equipment category "includes the measures and activities which provide an appropriate physical environment and resources used in the production of the drugs and drug products."3 See the sidebar for a list of the elements that FDA has grouped under the terms "Facilities" and "Equipment," which include such additional activity as environmental monitoring and IT asset management.

Biotech companies are realizing commonalities and interaction between the discipline and management of calibration, maintenance, and validation. For the most part, each group is working with the same set of assets, collecting a lot of the same profile information on the asset: description, ID, manufacturer, applications, etc. There are also similarities in how various groups work with assets: maintenance, calibration, and validation events occur for many assets on a set schedule, with a procedure or collection of procedures to follow for each event, with requirements for documented evidence that the event took place. These commonalities raise questions not only of efficiency, but also compliance concerns when identical data, with possible variations due to errors, are stored in multiple locations.

Taking a uniform approach to these activities and responsibilities is the first step toward achieving a complete and integrated facility and equipment system, on which regulatory audits will pivot.


blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

Bristol-Myers Squibb and Five Prime Therapeutics Collaborate on Development of Immunomodulator
November 26, 2014
Merck Enters into Licensing Agreement with NewLink for Investigational Ebola Vaccine
November 25, 2014
FDA Extends Review of Novartis' Investigational Compound for Multiple Myeloma
November 25, 2014
AstraZeneca Expands Biologics Manufacturing in Maryland
November 25, 2014
GSK Leads Big Pharma in Making Its Medicines Accessible
November 24, 2014
Author Guidelines
Source: BioPharm International,
Click here